Update Your Profile Member Spotlights Refer a Member: IASP Champions Join a Special Interest Group (SIG) Find a Chapter Join Now
PAIN PAIN Reports Pain Research Forum Papers of the Week Webinars and Podcasts Events
Online Learning - PERC Webinars & Podcasts Curricula Graduate Opportunities Events
RELIEF News Resources for Living with Pain Global Alliance of Partners in Pain Advocacy (GAPPA) Events
Support IASP Sponsor an Event Become a Partner
< BACK TO ARCHIVE
DATE PUBLISHED: 2022 Oct 22
JOURNAL:J Crohns Colitis
PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/36272109?dopt=Abstract
Upadacitinib is a selective Janus kinase inhibitor approved for the management of ulcerative colitis and under evaluation for the management of Crohn's disease in phase 3 clinical trials.